Back to search

University of Ioannina

Μελέτη βιολογικών δράσεων νέων μεταλλικών συμπλόκων του βαναδίου με κυτταροτοξικές ιδιότητες

Abstract

dc:description

In the present Doctoral Thesis the vanadium-complexes Pyrivan: {(pyH)6[VV10O28].2H2O} (1),Nicotivan: {(LH)4[VV10O26(OH)2].2L.2H2O} (2), Pipervan: {(L’H2)[(VO3)]2}n (3), Cadivan:{(L’’H2)3[VIV9VV6O36].14H2O} (4) and Azivan: {[VIV11VV7Na10O44(N3)(H2O)32].H2O}n (5), where L=Nicotinamide, py= Pyridine, L’= Butane-1,4-diamine and L’’= Pentane-1,5-diamine, where preparedby using NH4VO3 (for 1, 2 and 3) and VOSO4.4H2O (for 4 and 5), as starting materials, in varioussynthetic procedures. The putrescinic dication=L’H22+, that is present in 3 was formed in situ via ametal-assisted, complicated redox process, that involved the originally used piperazine, as areactant. The molecular and crystal structures of the complexes were determined by single-crystal,X-ray crystallography. Compounds 1, 2 and 4 contain discrete, homo- (1, 2) and hetero-valent (4)polyoxometalate anions, whereas complexes 3 and 5 have polymeric structures. The complexeswere characterized by IR, NMR and EPR spectra, by thermal decomposition techniques and byroom-temperature magnetic susceptibilities. All the data are discussed in terms of the compositionand known structures of the complexes. The VIV…VIV exchange interactions in cluster 4 are ofantiferromagnetic nature. In the present study five novel polyvanadate, with Nicotinamide, Pyridine,Piperazine, Cadaverine and Azides, as ligands were studied. The complexes named as: Nicotivan(1), Pyrivan (2), Pipervan (3), Cadivan (4) and Azivan (5) were synthesized and fully identified, andthese complexes are submitted bio-medical experimental examinations, in order to qualify theirantitumor , cytotoxic and antiplatelet actions on LMS malignamnt cells and human platelets.These complexes presented cytotoxic action in malignant LMS cells, but not any significant activity against fibroblasts. The IC50 in the LMS was: Cadivan (1,2250,238 κM) > Azivan (2,8 κM, LMScells) > Nicotivan (4,767 ± 0,525 κM) > Pyrivan (10,60,883 κM) > Pipervan (15,9 0,455 κM). InMCF-7 the IC50 were: Pyrivan (16,7 ± 0,23) > Pipervan (16,23 ± 0,74) > Nicotivan (6,93 ± 0,12) >Azivan (3,4 ± 0,37) > Cadivan (2.36 ± 0,37). In physiologic fibroblasts and in the MRC-5 line theIC50values of the novel complexes present activities, following the order: Pipervan (34,23 ± 1,35) >Azivan (12,93 ± 1,33) > Cadivan (2,43 ± 0,13) > Pyrivan (12,3 ± 0,21) > Nicotivan (9,83 ± 0,34). TheIC50 values of the five ligands present the following order: Piperazine (126,6 ±1,6) > Pyridine(107,6mM ±3,2) > Nicotinamide (47,4 mM ±1,3) > Cadaverine (10,8 mM ±0,4> Sodium Azide (2,3mM±0,7). In flow cytometry of LMS cells of Wistar rats all the complexes showed apoptotic phenomena.. In the apoptosis the activity of the complexes follows the order: Azivan (60,16%) > Pipervan >(57,97%) > Cadivan (53,76%) > Nicotivan (46,33%) > Pyrivan (43,75%), in comparison with theControl value, (3,22%).They also inhibit the human platelet aggregation, in the human plasma (exvivo),as follows:Nicotivan : The IC50 for PAF ranges between 1κM to 2κM, while for arachidonicacid (ARA) between 2 and 4 κM. The IC50, at which Nicotivan inhibits the action of ADP, rangesbetween 20 and 30 κM. Azivan : The IC50 for PAF ranges between 1κM - 2κM, while forarachidonic acid between 4 κM and 6 κM and for ADP between 4 and 10 κM. Pyrivan : The IC50 forPAF, ranges between 20 - 40 κM, while for arachidonic acid between 20 - 40 κM. Also the IC50 forADP ranges between 80 - 120 κM. Pipervan : The IC50 for PAF ranges between 20 κM and 40 κM,while for arachidonic acid between 20 κM - 40 κM. Also the IC50 value for ADP ranges between 200κM and 300 κM. Cadivan : The IC50 value for PAF ranges between 2 κM and 6 κM, while forarachidonic acid between 2 κM and 2,5 κM. Also the IC50 value for ADP ranges between 20 κM and40 κM. The organic ligands of these vanadium complexes, exhibited antiplatelet effects but thepresence of vanadium appears to promote the antiplatelet activity of these complexes. Consequentlythe studied vanadium complexes present significant cytotoxic properties, as well as inhibition ofplatelet aggregation.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Roubatis, Leonidas
  • Ρουμπάτης, Λεωνίδας

Subjects

dc:subject × 28

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40186

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Roubatis, Leonidas; Ρουμπάτης, Λεωνίδας. Μελέτη βιολογικών δράσεων νέων μεταλλικών συμπλόκων του βαναδίου με κυτταροτοξικές ιδιότητες. University of Ioannina, 2013. http://hdl.handle.net/10442/hedi/40186